___

1.Kaplan G, Newcorn JH. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder. Pediatr Clin North Am 2011; 58:99-120.

2. Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother 2014; 48:209-225.

3. Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol Suppl 1996; 102:9-21.

4. Clavenna A, Bonati M. Pediatric pharmacoepidemiology - safety and effectiveness of medicines for ADHD. Expert Opin Drug Saf 2017; 16:1335-1345.

5. Gross-Tsur V, Joseph A, Shalev RS. Hallucinations during methylphenidate therapy. Neurology 2004; 63:753-754.

6. Ross RG. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry 2006; 163:1149-1152.

7. Halevy A, Shuper A. Methylphenidate induction of complex visual hallucinations. J Child Neurol 2009; 24:1005-1007.

8. Porfirio MC, Giana G, Giovinazzo S, Curatolo P. Methylphenidateinduced visual hallucinations. Neuropediatrics 2011; 42:30-31.

9. Martinez-Aguayo JC, Arancibia M, Meza-Concha N, Bustamante C, Perez-Bracchiglione J, Madrid E. Brief psychosis induced by methylphenidate in a child with attention deficit disorder: a case report and literature review. Medwave 2017; 17:e6980.

10. Mosholder AD, Gelperin K, Hammad TA, Phelan K, JohannLiang R. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics 2009; 123:611-616.

11. Man KK, Coghill D, Chan EW, Lau WC, Hollis C, Liddle E, Banaschewski T, McCarthy S, Neubert A, Sayal K, Ip P, Wong IC. Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system. Transl Psychiatry 2016; 6:e956.

12. Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L, Ding Y, Gatley SJ, Gifford A, Franceschi D. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001; 21:RC121.

13. Groenman AP, Schweren LJ, Dietrich A, Hoekstra PJ. An update on the safety of psychostimulants for the treatment of attentiondeficit/hyperactivity disorder. Expert Opin Drug Saf 2017; 16:455-464.

14. Onder G, Pellicciotti F, Gambassi G, Bernabei R. NSAID-related psychiatric adverse events: who is at risk? Drugs 2004; 64:2619- 2627.

15. Braddock LE, Heard RN. Visual hallucinations due to indomethacin: a case report. Int Clin Psychopharmacol 1986; 1:263-266.

16. Tharumaratnam D, Bashford S, Khan SA. Indomethacin induced psychosis. Postgrad Med J 2000; 76:736-737.

17. Turkoglu G, Turkoglu S, Kayal S, Karahan AY. IndomethacinInduced Psychotic Disorder. Clin Neuropharmacol 2016; 39:161.

18. Ross BM, Brooks RJ, Lee M, Kalasinsky KS, Vorce SP, Seeman M, Fletcher PJ, Turenne SD. Cyclooxygenase inhibitor modulation of dopamine-related behaviours. Eur J Pharmacol 2002; 450:141-151.